Combined low initial DNA damage and high radiation-induced apoptosis confers clinical resistance to long-term toxicity in breast cancer patients treated with high-dose radiotherapy

Luis Alberto Henríquez-Hernández1,2,3*, Ruth Carmona-Vigo1, Beatriz Pinar1,2,3, Elisa Bordón1,2,3, Marta Lloret1,2,3, María Isabel Núñez4, Carlos Rodríguez-Gallego2,5 and Pedro C Lara1,2,3

Abstract

Background: Either higher levels of initial DNA damage or lower levels of radiation-induced apoptosis in peripheral blood lymphocytes have been associated to increased risk for develop late radiation-induced toxicity. It has been recently published that these two predictive tests are inversely related. The aim of the present study was to investigate the combined role of both tests in relation to clinical radiation-induced toxicity in a set of breast cancer patients treated with high dose hyperfractionated radical radiotherapy.

Methods: Peripheral blood lymphocytes were taken from 26 consecutive patients with locally advanced breast carcinoma treated with high-dose hyperfractionated radical radiotherapy. Acute and late cutaneous and subcutaneous toxicity was evaluated using the Radiation Therapy Oncology Group morbidity scoring schema. The mean follow-up of survivors (n = 13) was 197.23 months. Radiosensitivity of lymphocytes was quantified as the initial number of DNA double-strand breaks induced per Gy and per DNA unit (200 Mbp). Radiation-induced apoptosis (RIA) at 1, 2 and 8 Gy was measured by flow cytometry using annexin V/propidium iodide.

Results: Mean DSB/Gy/DNA unit obtained was 1.70 ± 0.83 (range 0.63-4.08; median, 1.46). Radiation-induced apoptosis increased with radiation dose (median 12.36, 17.79 and 24.83 for 1, 2, and 8 Gy respectively). We observed that those "expected resistant patients" (DSB values lower than 1.78 DSB/Gy per 200 Mbp and RIA values over 9.58, 14.40 or 24.83 for 1, 2 and 8 Gy respectively) were at low risk of suffer severe subcutaneous late toxicity (HR 0.223, 95%CI 0.073-0.678, P = 0.008; HR 0.206, 95%CI 0.063-0.677, P = 0.009; HR 0.239, 95%CI 0.062-0.929, P = 0.039, for RIA at 1, 2 and 8 Gy respectively) in multivariate analysis.

Conclusions: A radiation-resistant profile is proposed, where those patients who presented lower levels of initial DNA damage and higher levels of radiation induced apoptosis were at low risk of suffer severe subcutaneous late toxicity after clinical treatment at high radiation doses in our series. However, due to the small sample size, other prospective studies with higher number of patients are needed to validate these results.

* Correspondence: lhenriquez@dcc.ulpgc.es
1Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Spain
Full list of author information is available at the end of the article

© 2011 Henríquez-Hernández et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
Locally advanced breast cancer (LABC) is a relatively infrequently tumour which poses a significant clinical challenge. The management of LABC has evolved considerably. Initially, patients with LABC were treated with radical mastectomy [1,2]; thereafter, systemic therapy was subsequently incorporated along with surgery and radiotherapy (RT) [3]. However, even with such combined modality therapy, the long-term survival rate is approximately 50% among patients with LABC [4]. In cases with inadequate response to neoadjuvant systemic therapies and inability to perform surgery, RT is the only possible treatment [5].

Better local control outcomes, with acceptable toxicity, have been obtained by using high total doses of radiation administered in two small fractions per day (hyper-fractionation, HF) [6]. HF allows escalation of the biologically effective dose to the tumour without a significant increase in late complications [7]. The radio therapeutic doses received by the patient are limited by the tolerance of the normal tissues. Different patients given a standardized treatment can exhibit a range of normal acute and/or late tissue reactions [8,9]. Thus, there is both a dose dependence and a variability in individual radiosensitivity, where genetic [10,11] and constitutional factors [9,12] inherit to each patient could exert an influence.

The prediction of radiation-induced toxicity could help to select the most appropriate treatment for each patient. Many predictive factors have been described, including initial DNA damage [13], cell apoptosis [14], or gene expression patterns [15,16]. In previous studies, we have reported an association between the initial number of DNA double-strand breaks (DSB) induced by x-rays in peripheral blood lymphocytes (PBL) and radiation-toxicity [17,18]. Thus, increasing numbers of radiation induced DSB were related to severe late subcutaneous toxicity in LABC patients treated with HF [18]. In the other hand, determination of radiation-induced apoptosis (RIA) in PBL by flow cytometry analysis has also been proposed as an approach for predicting normal tissue responses following radiotherapy [19,20]. Patients suffering of late toxicity after RT showed reduced rates of RIA in several tumour locations [20-22]. Moreover, we have recently reported an inverse association between the initial DNA damage and RIA in LABC patients [23].

Table 1 Characteristics of patients studied

|                | N (%) | Mean ± SD | Median (Range) |
|----------------|-------|-----------|----------------|
| Age            | 57.62 ± 12.9 | 60 (30-83) |
| <60 years      | 12 (46.2)    |           |                |
| ≥60 years      | 14 (53.8)    |           |                |
| Menopause      |         |           |                |
| Premenopausal  | 8 (30.8)     |           |                |
| Postmenopausal | 18 (69.2)    |           |                |
| Tumor type     |         |           |                |
| Inflammatory   | 7 (26.9)     |           |                |
| Non-inflammatory | 19 (73.1)  |           |                |
| Tumor size     |         |           |                |
| T3             | 1 (3.8)      |           |                |
| T4a-T4b        | 18 (69.2)    |           |                |
| T4c-T4d        | 7 (27.0)     |           |                |
| Nodes          |         |           |                |
| N0             | 18 (69.2)    |           |                |
| N1-N2          | 8 (30.8)     |           |                |
| Metastasis     |         |           |                |
| M0             | 24 (92.3)    |           |                |
| M1             | 2 (7.7)      |           |                |
| Bra size       |         | 100 ± 10.6 | 100 (80-120)   |
| <100           | 9 (34.6)     |           |                |
| ≥100           | 17 (65.4)    |           |                |
| Systemic treatment |    |           |                |
| Chemotherapy   | 4 (15.4)     |           |                |
| Hormonal therapy | 5 (19.2)   |           |                |
| Chemotherapy-hormonal therapy | 17 (65.4) |           |                |
| Received dose (Gy) | 78.48 ± 5.7 | 81.60 (64.8-81.6) |
| <81.6          | 7 (26.9)     |           |                |
| ≥81.6          | 19 (73.1)    |           |                |
| Maximum dose (Gy) | 87.36 ± 8.8 | 89.76 (62.8-101.7) |
| <89.8          | 15 (57.7)    |           |                |
| ≥89.8          | 11 (42.3)    |           |                |

Methods
Characteristics of Patients
Twenty-six consecutive patients diagnosed in our institution with locally advanced/inflammatory breast cancer were recruited prospectively for the study after they signed informed consent to their participation. The study was approved by the Research and Ethics Committee of our Institution. All patients were treated between 1992 and 1997; blood samples for radiosensitivity testing were extracted between February and December 1998. All the analyses were double-blinded to ensure their reliability. Mean age of patients was 57.62 ± 12.9 years (range 30-83). The majority of patients were postmenopausal (69.2%), presented bra size over 100 (65.4%), and
non-inflammatory LABC (73.1%). Characteristics of patients are detailed in Table 1. Evaluation of clinical toxicity was made in each visit. The Radiotherapy Oncology Group (RTOG) morbidity score system was used to classify the toxicity of patients. Acute toxicity was evaluated during and at the end of RT. Late cutaneous and subcutaneous toxicity was evaluated every three months during the first two years, every six months to five years, and thereafter annually. At the end of the analysis (January 2011), the mean clinical follow-up of survivors (n = 13) was 197.23 months (range 155-228). The time point finally used for analysis corresponds to the last evaluation. Clinical toxicities of patients are detailed in Table 2.

Radiation Treatment
Patients were treated with a dose-escalation radiation therapy schedule using hyperfractionation. All patients received 60 Gy to the whole breast over a period of 5 weeks in two daily fractions of 1.2 Gy, separated by at least 6 h on 5 days each week. A boost covering the tumour plus margins was prescribed at a dose of 9.4-21.6 Gy [17]. Peripheral nodes were treated by conventional fractionation (1.8/2Gy/day) at doses of 50-70 Gy. Supraclavicular and axillary lymph node areas were treated with an anterior field and a posterior axillary compensating field. Doses to the breast mammary chain was treated by a direct anterior field with a posterior compensation field. Three-dimensional planning was used for the breast and the supraclavicular area. The internal mammary chain was treated by a direct anterior field with a posterior compensation field. The dose prescribed at depth of 3 cm. Doses to the breast ranged from 64.8 Gy to 81.6 Gy (mean 77.5 ± 5.7 Gy; median 81.6 Gy). Maximum point doses ranged from 62.8 to 101.7 Gy (mean 87.4 ± 8.8; median 89.7 Gy).

Analysis of Initial DNA Damage
Data related to initial DNA damage were obtained from our files [17]. Shortly, mononuclear cells were isolated from blood of patients, resuspended in cold DMEM, and mixed with 1% ultra-low-melting-point agarose to obtain 250 μl plugs. Irradiation on ice was performed using a 60Co source (rate dose 1.5 Gy/min, approximately) as previously reported [17]. Plugs were held 1 hour at 4°C and incubated at 37°C for 24 hours. Initial radiation-induced DNA damage in PBL was measured by pulsed-field gel electrophoresis (PFGE) as previously described [24], and data are summarized in Table 3.

Apoptosis assay and flow cytometry
RIA analyses were performed as previously reported [21,22]. PBL were irradiated with 0, 1, 2 and 8 Gy. After irradiation, samples were incubated for 24 hours at 37°C and 5% CO2. After extraction of cellular pellet, it was resuspended in 100 μl Annexin V buffer Kit (Pharmingen, Becton Dickinson). After the addition of 4 μl of Annexin-V-FITC and 10 μl of propidium iodure (PI), cells were incubated during 15 minutes at room temperature in the dark. Finally, 400 μl of Annexin V buffer Kit were added. Every assay was made in triplicate.

The flow cytometry analysis was performed in a FACScalibur (Becton Dickinson, San José, CA) using a 488 nm argon laser, and each sample was analyzed in a Macintosh Quadra 650 minicomputer (Apple computer Inc., Cupertino, CA) as previously reported [25]. Data were analyzed using the CellQuest program (Becton Dickinson, San José, CA) calculating early and late apoptosis levels. RIA is defined as the percentage of total PBL death induced by the radiation dose minus the spontaneous cell death (control, 0 Gy).

Statistical analyses
Statistical analyses were performed using the SPSS Statistical Package (version 15.0 for Windows). The cut-off values for continuous variables were the median and the tertiles of the distribution, as previously reported [17,23]. Univariate and multivariate analyses were performed using Cox regression. All tests were two sided and statistical significance level was established for a P value less than 0.05. All samples were processed anonymously.

Results and Discussion
Radiation-induced toxicity in breast cancer patients
The actuarial probability of being free of severe late cutaneous toxicity, nine-teen years after radiation therapy, was 61.5%, while only 19.2% were free of severe late

| Grade | Acute Toxicity | Late Toxicity |
|-------|----------------|---------------|
|       | Cutaneous      | Cutaneous     | Subcutaneous |
| 1     | 6 (23.1)       | 0 (0.0)       | 1 (3.8)      |
| 2     | 12 (46.2)      | 16 (61.5)     | 5 (19.3)     |
| 3     | 8 (30.8)       | 10 (38.5)     | 19 (73.1)    |
| 4     | 0 (0.0)        | 0 (0.0)       | 1 (3.8)      |

Numbers in brackets represent the percentage.
subcutaneous toxicity. In a previous observation, 10 years after RT [17], 65% of patients were free of severe late cutaneous toxicity ($\chi^2$ test, $P = 0.463$); while 29% were free of severe late subcutaneous toxicity ($\chi^2$ test, $P = 0.031$). Severe subcutaneous toxicity is related to breast shrinkage, fibrosis and sometimes pain. Late radiation-induced reaction occurs after a latency period of >90 days (typical range 0.5-5 years). The latency period in animals is known to be shorter after higher doses, and in humans, it is even >5 years for moderate doses or for very late reacting tissues. Late damage progresses over time, and it is important to highlight that doses believed safe at 5 years may result in serious late side effects beyond the 5-year period with any treatment protocol [26]. For this, the ability to predict late effects in the treated breast is of great importance, especially when an unconventional treatment schedule is prescribed. In univariate analysis (simple Cox regression), severe subcutaneous late toxicity (grades 3-4) was related to bra size-estimated breast volume ($P = 0.037$) (Table 4). Breast size is strongly related to late changes in breast appearance possible because greater radiation changes are related to greater dose inhomogeneity in women with large breasts [12,17,27].

**Initial DNA damage levels in breast cancer patients**

Initial DNA damage was determined as radiation-induced double-strand breaks (DSB) in irradiated lymphocyte from all 26 LABC patients. There was a wide variation in DSB among patients (Table 3) with a mean value of 1.70 ± 0.83 DSB/Gy per 200 Mbp (median, 1.46; range, 0.63-4.08). These results support the suggestion that variation in cell radiosensitivity can be detected in vitro using radiosensitivity assays on lymphocytes derived from normal tissues of cancer patients prior to radiotherapy [18,28-30]. This wide variation in DNA DSB can be attributed to variation between individuals more than to variation due to technical or sampling errors [18,31,32]. Initial DNA damage followed a normal distribution (Kolmogorov-Smirnov test, $P > 0.05$), and data obtained from the present group of patients matched previously published results for breast cancer patients [17,18]. However, other molecular events such as DNA repair foci or DNA-loops should be taken into account for the correct interpretation of data. It has been observed that DNA DSB in residual foci and relaxation of DNA-loops may be linked to induction of radiation-induced apoptosis in lymphocytes [33-35].

We have previously demonstrated a relation between the sensitivity of in vitro-irradiated peripheral blood lymphocytes and the risk of developing late toxic effects after RT in the present set of patients [17]. However, the predictive value of initial DNA damage is controversial and different findings have been reported on this regard. Thus, we agree with some authors [28,30,36] and we disagree with some others [37]. Moreover, more initial DSB have been detected in lymphocytes from normal patients as compared to radiosensitive [38]. In our opinion, it is important to highlight that the predictive role of initial DNA damage was observed in patients treated with high-dose of radiation, where the toxicity reactions are more evident. Differences in the protocol treatment (RT schedule: dose and type of fractionation) and in the methodology used (PFGE, comet assay, gamma-H2AX induction) could help to explain the discrepancies observed.

**Radiation-induced apoptosis in breast cancer patients**

Data of RIA were available in all 26 breast cancer patients as shown in Table 3. RIA increased with radiation dose and data fitted to a semi logarithmic model as follows: $RIA = \beta \ln(\text{Gy}) + \alpha$. This mathematical model was defined by two constants: the coefficient in origin $\alpha$ (determining the spontaneous apoptosis) and the coefficient $\beta$ (defining the slope of the curve) [21,22,25,39]. As expected, RIA at 1, 2 and 8 Gy, as well as $\alpha$ and $\beta$ constants followed a normal distribution (Kolmogorov-Smirnov test, $P > 0.05$). There is an important variation in the ex vivo susceptibility of normal cells against ionizing radiation. It has been suggested that the radiation-induced damage measured on lymphocytes could be proportional to the acute damage evaluated on the skin of treated patients [40]. Anyhow, it is possible to estimate the cellular radiosensitivity of PBL of patients analyzing the RIA rate by annexin V/PI staining flow cytometric analysis, defining an intrinsic individual value of radiosensitivity inherit to each patient.

Radiation-induced apoptosis has been proposed as a reliable method for prediction of normal tissue toxicity after radiotherapy by us [21,22] and other authors [14,19,20]. However, some other studies reported no correlations between individual radiosensitivity of cancer patients and radiation-induced apoptosis in PBLs [41,42]. The lack of uniformity in experimental design helps to understand these differences. Thus, the cells used in the assay (total PBL, Epstein-Barr virus-transformed

**Table 4 Distribution of patients according to expected radiation sensitivity after the irradiation of peripheral blood lymphocytes at 1, 2 and 8 Gy**

| Expected radiation sensitivity | RIA 1 Gy | RIA 2 Gy | RIA 8 Gy |
|-------------------------------|---------|---------|---------|
| High († DSB, ↓ RIA)           | 2       | 1       | 3       |
| Intermediate*                 | 13      | 15      | 10      |
| Low (↓ DSB, ↑ RIA)            | 11      | 10      | 13      |
|                               | 26      | 26      | 26      |

Abbreviations: DSB = DNA double-strand breaks; RIA = radiation-induced apoptosis.

*Intermediate: patients showing † DSB, ↑ RIA; or ↓ DSB, ↓ RIA.
lymphoblastoid cell lines, CD(3+) lymphocytes), the radiation protocol, or the analysis strategy are critical to make possible the comparison among studies.

**Association of initial DNA damage and radiation-induced apoptosis with normal tissue toxicity**

As previously published, increasing numbers of radiation induced DSB were related to severe late toxicity in breast cancer patients [17]. Thus, among patients receiving the highest radiation doses (81.6 Gy), those who showed higher levels of initial DNA damage had a greater risk of severe subcutaneous toxicity. In the present set of patients, no association was observed between DNA DSB or RIA (at any radiation dose), α or β constants and normal tissue toxicity, possibly due to the small sample size (data not shown). An association between the initial DNA damage and the radiation-induced apoptosis, as a consequence of x-ray, may exist [43,44]. DNA DSB are assumed to be the most important lesion to induce apoptosis [45]. Depending on the severity of the DNA damage and the cell type involved, cells may undergo apoptosis instead of attempting to repair the damage [46]. Lymphocytes are particularly sensitive to apoptosis, partly because they induce Bax expression in response to ionizing radiation exposure [46]. Lymphocytes from patients who suffered Ataxia-telangiectasia, Bloom syndrome, or Fanconi anaemia showed absence of induction of p53 and lower levels of Bax [47-49]. Apoptosis is initiated following DSB through an ATM-directed pathway [50]. This could explain the fact that patients affected by the Ataxia-Telangiectasia syndrome show the lowest rates of RIA. In that sense, we have recently reported an inverse association between the initial DNA damage and RIA in LABC patients [23]. Defective apoptotic response to radiation in PBLs could help to explain this inverse relation [14].

According to the above observations, high initial DNA damage [17] or low radiation-induced apoptosis [14,20-22,25,51] would confer sensitivity to long-term toxicity, separately. In the present study, we tried to disclose the predictive value of both parameters in a combined form. The percentage of patients developing severe late toxicity determines the maximum acceptable radiation dose. Generally, an adverse effect frequency of 5%-10% is considered acceptable [52]. We observed that 7.6% (range 3.8-11.5%) of our patients suffered from severe complications (2, 1, and 3 out of 26 patients analyzed at 1, 2 and 8 Gy respectively) (Table 4). Because this subset of patients is too small, we focused on the expected most resistant patients to RT: those who presented low initial DNA damage and high radiation-induced apoptosis (Table 4). Thus, we considered "resistant patients" those who presented DSB values lower than 1.78 DSB/Gy per 200 Mbp (two lower thirds of the distribution) and RIA values over 9.58, 14.40 or 24.83 for 1, 2 and 8 Gy respectively (two upper thirds of the distribution) (Table 3). We did not observe any association with late toxicity in the whole series, in univariate analysis. However, order to the higher received dose (≥81.6 Gy), we observed that severe subcutaneous late toxicity (grades 3-4) was related to this radiation-resistance profile in patients treated with higher dose of radiation (simple Cox regression, Table 5). Those patients treated at very high doses (≥81.6 Gy) and who presented this radiation-resistance pattern were at low risk of suffer severe subcutaneous late toxicity (Table 5). Furthermore, in multivariate analysis in the whole series, severe subcutaneous late toxicity was related to the received dose (HR 1.138, 95%CI 1.003-1.291, P = 0.045), the bra size-estimated volume (HR 1.073, 95%CI 1.004-1.147, P = 0.038), and with this radiation-resistant profile (HR 0.223, 95%CI 0.073-0.678, P = 0.008; HR 0.206, 95%CI 0.063-0.677, P = 0.009; HR 0.239, 95%CI 0.062-0.929, P = 0.039, for RIA at 1, 2 and 8 Gy, respectively) (Table 6). Thus, those patients who presented lower levels of initial DNA damage and higher levels of radiation induced apoptosis were at low risk of suffer severe subcutaneous late toxicity. No relation was found with acute or late cutaneous toxicity. The close relation between chromosome fragment production and killing in many cell systems has been important in linking DNA DSB to death, because it is a natural step to relate DNA strand breakage to chromosome breakage. However, the recognition that apoptosis may be an important mode of radiation-induced death in some cell types raise the possibility that other types of damage may induce apoptosis [13]. A significant association was

| Table 5 Univariate analysis for grades 3-4 late subcutaneous toxicity in the whole series of patients (n = 26) and in patients who received higher doses of RT (n = 19) |
|---------------------------------|----------------|----------------|
| Whole series                    | HR (95% CI)    | P              |
| Age                             | 1.012 (0.975-1.012) | 0.535          |
| Received dose                   | 1.079 (0.980-1.189) | 0.123          |
| Maximum dose                    | 1.054 (0.991-1.121) | 0.096          |
| Bra size                        | 1.056 (1.003-1.111) | 0.037          |
| Systemic treatment              | 1.084 (0.351-3.347) | 0.888          |
| Low DSB-High RIA 1Gy            | 0.564 (0.233-1.370) | 0.206          |
| Low DSB-High RIA 2Gy            | 0.510 (0.204-1.277) | 0.150          |
| Low DSB-High RIA 8Gy            | 0.642 (0.270-1.523) | 0.314          |
| Higher dose (≥81.6Gy)           |                |                |
| Low DSB-High RIA 1Gy            | 0.252 (0.077-0.826) | 0.023          |
| Low DSB-High RIA 2Gy            | 0.197 (0.053-0.735) | 0.016          |
| Low DSB-High RIA 8Gy            | 0.240 (0.074-0.778) | 0.017          |

Abbreviations: HR = hazard ratio; CI = confidence interval.
Table 6 Multivariate analysis for grades 3-4 late subcutaneous toxicity in the whole series of patients (n = 26)

| Whole series | HR (95% CI) | P |
|--------------|-------------|---|
| Age          | 1.044 (0.986-1.106) | 0.139 |
| Received dose | 1.138 (1.003-1.291) | 0.045 |
| Bra size     | 1.073 (1.004-1.147) | 0.038 |
| Systemic treatment | 1.155 (0.199-6.697) | 0.873 |
| Low DSB-High RIA 1Gy | 0.223 (0.073-0.678) | 0.008 |
| Low DSB-High RIA 2Gy | 0.206 (0.063-0.677) | 0.009 |
| Low DSB-High RIA 8Gy | 0.239 (0.062-0.929) | 0.039 |

Abbreviations: HR = hazard ratio; CI = confidence interval.

observed for the first time between these variables, both considered as predictive factors for radiation toxicity, and normal tissue damage.

Conclusions

Initial DNA double-strand breaks and radiation-induced apoptosis in peripheral blood lymphocytes have been proposed as reliable methods for prediction of radiation-induced late toxicity in normal tissues [11,17,20]. We have observed, for the first time, a combined role of both parameters. Thus, we propose a radiation-resistance profile where those patients who present lower levels of initial DNA damage and higher levels of radiation induced apoptosis were at low risk of suffer severe subcutaneous late toxicity in our series. This finding opens the possibility to develop new predictor assays taking into account the initial DNA damage and radiation-induced apoptosis levels, and introduces new data which may help to understand and define the complex mechanisms behind the normal tissue toxicity. Nonetheless, due to the small sample size, the present results need to be validated in bigger clinical series.

List of abbreviations

DSB: double-strand Break; HF: hyperfractionation; HR: hazard ratio; CI: confidence interval; LABC: locally advanced breast cancer; PRL: peripheral blood lymphocytes; PI: propidium iodide; RIA: radiation-induced Apoptosis; RT: radiotherapy.

Acknowledgements

This work was subsidized by a grant from the Ministerio de Educación y Ciencia (CICYT: SAF 2004-00889) and Fundación del Instituto Canario de Investigación del Cáncer (FICIC).

Authors’ contributions

LAHH has written the manuscript, has participated in the statistical analysis, has made tables and has been involved in type of packaging likewise in the submission process. ROC has made the last revision of patients as well as the update of the medical records. BP and ML have made the selection of patients, the evaluation of clinical variables and grade of toxicity as well as all the aspects related with the patients selected, including the treatment. EB and CRG have made the cell experiments with lymphocytes, irradiation of cells, flow cytometry experiments and data acquisition. MIN has been involved in conception and design of the study and has made the DNA-DSB experiments and analyses. PCL has been involved in conception and design of the study and in drafting the manuscript and has given final approval of the version to be published. All authors read and approved the final manuscript.

Competing interests

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Received: 26 January 2011 Accepted: 6 June 2011 Published: 6 June 2011

References

1. Haagensen CD, Stout AP. Carcinoma of the Breast. Il-Criteria of Operability. Ann Surg 1943, 118:1032-1051
2. Haagensen CD, Stout AP. Carcinoma of the Breast: Il. Criteria of Operability. Ann Surg 1943, 118:859-870.
3. Toonkel LM, Fix I, Jacobson LH, Bamberg N, Wallach CB. Locally advanced breast carcinoma: results with combined regional therapy. Int J Radiat Oncol Biol Phys 1986, 12:1583-1587.
4. Therasse P, Mauriac L, Welinka-Jaszkiewicz M, Bruning P, Cufer T, Bonnefoi H, Tomiak E, Pichard KL, Hamilton A, Piccart MJ. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensiﬁed epirubicin and cyclophosphamide + ﬁlagristim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003, 21:843-850.
5. Shenker T, Weir L, Levine M, Olivotto I, Whelan T, Reyna L. Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment of women for stage III or locally advanced breast cancer. CA MA 2004, 107:983-994.
6. Baumann M, Bentzen SM, Ang KK. Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. Radiother Oncol 1998, 46:127-130.
7. Burnet NG, Johansen J, Turesson I, Nyman J, Peacock JH. Describing patients’ normal tissue reactions: concerning the possibility of individualising radiotherapy dose prescriptions based on potential predictive assays of normal tissue radiosensitivity. Steering Committee of the BioMed2 European Union Concerted Action Programme on the Development of Predictive Tests of Normal Tissue Response to Radiation Therapy. Int J Cancer 1998, 79:606-613.
8. Burnet NG, Johansen J, Turesson I, Nyman J, Peacock JH. Describing patients’ normal tissue reactions: concerning the possibility of individualising radiotherapy dose prescriptions based on potential predictive assays of normal tissue radiosensitivity. Steering Committee of the BioMed2 European Union Concerted Action Programme on the Development of Predictive Tests of Normal Tissue Response to Radiation Therapy. Int J Cancer 1998, 79:606-613.
26. Johansson S, Svensson H, Denekamp J: Nunez MI, Guerrero MR, Lopez E, del Moral MR, Valenzuela MT, Villalobos M, Guerrero R, Luna JD, Ruiz de Almodovar JM: Radiation-induced DNA damage as a predictor of long-term toxicity in locally advanced breast cancer patients treated with high-dose hyperfractionated radical radiotherapy. Radiat Oncol 2009, 4:17.

27. Pinar B, Lara PC, Lloret M, Bordon E, Park B, Bordon E, de Almodovar JM: Radiation-induced apoptosis in peripheral blood lymphocytes in normal individuals, ataxia telangiectasia homologues and heterozygotes, and breast cancer patients after radiotherapy. Radiat Res 2000, 153:570-578.

18. Ruiz de Almodovar JM, Guirado D, Isabel Nunez M, Lopez E, Guerrero R, Valenzuela MT, Villalobos M, del Moral R: Individualization of radiotherapy in breast cancer patients: possible usefulness of a DNA damage assay to measure normal cell radiosensitivity. Radioter Oncol 2002, 62:327-333.

29. Hoeller U, Borgmann K, Bonacker M, Kuhlmey A, Bajrovic A, Jung H, Valloracerma MT, Munoz-Garcia D, Ruiz de Almodovar JM: Early and late skin reactions to radiotherapy for breast cancer and their correlation with radiation-induced DNA damage in lymphocytes. Breast Cancer Res 2005, 7:R690-698.

28. Dickson J, Magee B, Stewart A, West CM: Radiation-induced apoptosis, residual 53BP1 foci and DNA-loop relaxation in human lymphocytes. Int J Radiat Oncol Biol Phys 2009, 74:1489-1501.

21. Bordon E, Henriquez Hernandez LA, Lara PC, Pinar B, Fontes F, Rodriguez-Gallego C, Luna JD, Ruíz de Almodovar JM: Radiation-induced DNA damage as a predictor of long-term toxicity in locally advanced breast cancer patients treated with high-dose hyperfractionated radical radiotherapy. Radiat Oncol Res 2007, 168:415-422.

22. Bordon E, Henriques Hernandez LA, Lara PC, Pinar B, Fontes F, Rodriguez-Gallego C, Lloret M: Prediction of clinical toxicity in localized cervical carcinoma by radio-induced apoptosis study in peripheral blood lymphocytes (PBLs). Radiat Oncol 2009, 4:56.
50. Cann KL, Hicks GG: Regulation of the cellular DNA double-strand break response. Biochem Cell Biol 2007, 85:663-674.
51. Crompton NE, Shi YQ, Emery GC, Wissel L, Blatmann H, Maier A, Li L, Schindler D, Özsahin H, Özsahin M: Sources of variation in patient response to radiation treatment. Int J Radiat Oncol Biol Phys 2001, 49:547-554.
52. Svensson JP, Stalpers LJ, Esveldt-van Lange RE, Franken NA, Haveman J, Klein B, Turesson I, Vrieling H, Giphart-Gassler M: Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Med 2006, 3:e422.

doi:10.1186/1748-717X-6-60
Cite this article as: Henríquez-Hernández et al.: Combined low initial DNA damage and high radiation-induced apoptosis confers clinical resistance to long-term toxicity in breast cancer patients treated with high-dose radiotherapy. Radiation Oncology 2011, 6:60.